325 related articles for article (PubMed ID: 28440963)
1. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
Kou T; Kanai M; Yamamoto Y; Kamada M; Nakatsui M; Sakuma T; Mochizuki H; Hiroshima A; Sugiyama A; Nakamura E; Miyake H; Minamiguchi S; Takaori K; Matsumoto S; Haga H; Seno H; Kosugi S; Okuno Y; Muto M
Cancer Sci; 2017 Jul; 108(7):1440-1446. PubMed ID: 28440963
[TBL] [Abstract][Full Text] [Related]
2. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
5. Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Park HS; Lim SM; Kim S; Kim S; Kim HR; Kwack K; Lee MG; Kim JH; Moon YW
PLoS One; 2016; 11(4):e0154133. PubMed ID: 27105424
[TBL] [Abstract][Full Text] [Related]
6. Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
Quy PN; Kanai M; Fukuyama K; Kou T; Kondo T; Yamamoto Y; Matsubara J; Hiroshima A; Mochizuki H; Sakuma T; Kamada M; Nakatsui M; Eso Y; Seno H; Masui T; Takaori K; Minamiguchi S; Matsumoto S; Muto M
Oncologist; 2019 Dec; 24(12):e1401-e1408. PubMed ID: 31186376
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
8. Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
Rodler S; Jung A; Greif PA; Rühlmann K; Apfelbeck M; Tamalunas A; Kretschmer A; Schulz GB; Szabados B; Stief C; Heinemann V; Westphalen CB; Casuscelli J
Eur J Cancer; 2021 Mar; 146():1-10. PubMed ID: 33535139
[TBL] [Abstract][Full Text] [Related]
9. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.
Takeda M; Sakai K; Terashima M; Kaneda H; Hayashi H; Tanaka K; Okamoto K; Takahama T; Yoshida T; Iwasa T; Shimizu T; Nonagase Y; Kudo K; Tomida S; Mitsudomi T; Saigo K; Ito A; Nakagawa K; Nishio K
Ann Oncol; 2015 Dec; 26(12):2477-82. PubMed ID: 26420428
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.
Bieg-Bourne CC; Millis SZ; Piccioni DE; Fanta PT; Goldberg ME; Chmielecki J; Parker BA; Kurzrock R
Cancer Res; 2017 Nov; 77(22):6313-6320. PubMed ID: 28939679
[TBL] [Abstract][Full Text] [Related]
12. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Lih CJ; Takebe N
Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
[TBL] [Abstract][Full Text] [Related]
13. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
15. Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients.
Palmieri M; Baldassarri M; Fava F; Fabbiani A; Gelli E; Tita R; Torre P; Petrioli R; Hadijstilianou T; Galimberti D; Cinotti E; Bengala C; Mandalà M; Piu P; Miano ST; Martellucci I; Vannini A; Pinto AM; Mencarelli MA; Marsili S; Renieri A; Frullanti E
Cancer Med; 2020 Mar; 9(6):2052-2061. PubMed ID: 31991072
[TBL] [Abstract][Full Text] [Related]
16. Implementation of clinical sequencing for molecular profiling in patients with advanced cancer.
Fukui T; Sakai K; Sasaki J; Kakegawa MI; Igawa S; Mitsufuji H; Takeda M; Takahama T; Nakagawa K; Nishio K; Naoki K
Cancer Biomark; 2021; 31(2):119-126. PubMed ID: 33896820
[TBL] [Abstract][Full Text] [Related]
17. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
18. Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan.
Kato S; Hayashi T; Suehara Y; Hamanoue H; Yamanaka S; Ichikawa Y; Higurashi T; Ohashi K; Yamaguchi S; Nozaki Y; Terao Y; Saito T
Jpn J Clin Oncol; 2019 Feb; 49(2):174-182. PubMed ID: 30541038
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.
Kanagal-Shamanna R; Portier BP; Singh RR; Routbort MJ; Aldape KD; Handal BA; Rahimi H; Reddy NG; Barkoh BA; Mishra BM; Paladugu AV; Manekia JH; Kalhor N; Chowdhuri SR; Staerkel GA; Medeiros LJ; Luthra R; Patel KP
Mod Pathol; 2014 Feb; 27(2):314-27. PubMed ID: 23907151
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
